- Recommendation ID
- NG78/1
- Question
Liver disease:- Should all children with meconium ileus receive ursodeoxycholic acid from diagnosis?
- Any explanatory notes
(if applicable) Why this is important:- Liver disease is the third most common cause of mortality in people with cystic fibrosis, and around 10 to 30% of people with cystic fibrosis will develop cystic-fibrosis-related liver disease. Children with meconium ileus are at an increased risk of liver disease, and starting treatment with ursodeoxycholic acid from diagnosis may reduce this risk. Ursodeoxycholic acid appears safe, is well tolerated and cheap. Routine use could increase people's overall quality of life and reduce the
need for subsequent treatment for liver disease, but more research is needed into the effectiveness and safety of this treatment.
Source guidance details
- Comes from guidance
- Cystic fibrosis: diagnosis and management
- Number
- NG78
- Date issued
- October 2017
Other details
| Is this a recommendation for the use of a technology only in the context of research? | No |
| Is it a recommendation that suggests collection of data or the establishment of a register? | No |
| Last Reviewed | 31/10/2017 |